论文部分内容阅读
目的探究血塞通联合盐酸氟桂利嗪在偏头痛治疗中的临床效果。方法选择2016年3月—2017年1月收治的偏头痛患者124例,根据随机数字表法分为对照组和观察组各62例。对照组给予盐酸氟桂利嗪胶囊治疗,观察组在对照组基础上给予血塞通胶囊治疗。比较两组临床疗效、血液流变学指标、头痛发作情况及安全性。计数资料比较采用χ~2检验,计量资料比较采用t检验,P<0.05为差异有统计学意义。结果观察组红细胞压积、血浆黏度、纤维蛋白原、VAS评分、发作持续时间、发作频率[(36.52±5.03)%、(3.56±0.98)m Pa·s、(2.21±0.99)g/L、(3.21±1.03)分、(4.09±1.95)h、(8.24±3.64)次/月]均低于对照组[(45.68±4.62)%、(4.62±1.06)m Pa·s、(2.96±1.06)g/L、(4.69±1.22)分、(6.57±1.12)h、(11.64±4.96)次/月](均P<0.05);观察组临床总有效率(93.55%)高于对照组(80.65%)(P<0.05)。结论血塞通联合盐酸氟桂利嗪能提高偏头痛的临床治疗效果,改善血液流变学指标,减少头痛发作频率和疼痛程度,缩短头痛持续时间。
Objective To explore the clinical effect of Xuesaitong combined with flunarizine hydrochloride in the treatment of migraine. Methods 124 patients with migraine who were admitted from March 2016 to January 2017 were divided into control group and observation group according to the random number table method. The control group was treated with Flunarizine Hydrochloride Capsule. The observation group was treated with Xuesaitong Capsule on the basis of the control group. The clinical curative effect, hemorheology index, headache attack and safety of the two groups were compared. Counting data were compared using χ ~ 2 test, measurement data were compared using t test, P <0.05 for the difference was statistically significant. Results The hematocrit, plasma viscosity, fibrinogen, VAS score, duration of attack, frequency of seizure [(36.52 ± 5.03)%, (3.56 ± 0.98) mPa · s and (2.21 ± 0.99) g / (3.21 ± 1.03), (4.09 ± 1.95) h, (8.24 ± 3.64) / month] were lower than those in the control group [(45.68 ± 4.62)%, (4.62 ± 1.06) mPa · s, (2.96 ± 1.06 ) (P <0.05). The total clinical effective rate (93.55%) in the observation group was higher than that in the control group (P <0.05) 80.65%) (P <0.05). Conclusion Xuesaitong combined with flunarizine hydrochloride can improve the clinical effect of migraine, improve the indexes of hemorheology, reduce the frequency and degree of headache attack and shorten the duration of headache.